| Inhibition of cancer antioxidant defense by natural compounds A Sznarkowska, A Kostecka, K Meller, KP Bielawski Oncotarget 8 (9), 15996, 2016 | 244 | 2016 |
| p73 tumor suppressor protein: a close relative of p53 not only in structure but also in anti-cancer approach? J Zawacka-Pankau, A Kostecka, A Sznarkowska, E Hedström, A Kawiak Cell Cycle 9 (4), 720-728, 2010 | 96 | 2010 |
| Regulation of Bcl-2 family proteins in estrogen receptor-positive breast cancer and their implications in endocrine therapy A Kawiak, A Kostecka Cancers 14 (2), 279, 2022 | 39 | 2022 |
| JNK–NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress A Kostecka, A Sznarkowska, K Meller, P Acedo, Y Shi, ... Cell death & disease 5 (10), e1484-e1484, 2014 | 38 | 2014 |
| Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells A Sznarkowska, A Kostecka, A Kawiak, P Acedo, M Lion, A Inga, ... Cell Division 13, 1-12, 2018 | 22 | 2018 |
| High prevalence of somatic PIK3CA and TP53 pathogenic variants in the normal mammary gland tissue of sporadic breast cancer patients revealed by duplex … A Kostecka, T Nowikiewicz, P Olszewski, M Koczkowska, M Horbacz, ... NPJ Breast Cancer 8 (1), 76, 2022 | 13 | 2022 |
| Adipose-derived mesenchymal stromal cells in clinical trials: Insights from single-cell studies A Kostecka, N Kalamon, A Skoniecka, M Koczkowska, PM Skowron, ... Life Sciences, 122761, 2024 | 5 | 2024 |
| Size matters: the impact of nucleus size on results from spatial transcriptomics E Mohammadi, K Chojnowska, M Bieńkowski, A Kostecka, M Koczkowska, ... Journal of Translational Medicine 21 (1), 270, 2023 | 3 | 2023 |
| Personalized health risk assessment based on single-cell RNA sequencing analysis of a male with 45, X/48, XYYY karyotype M Koczkowska, M Jąkalski, D Birkholz-Walerzak, A Kostecka, M Iliszko, ... Scientific reports 12 (1), 20854, 2022 | 3 | 2022 |
| Prelude to malignancy: A gene expression signature in normal mammary gland from breast cancer patients suggests pre‐tumorous alterations and is associated with adverse outcomes M Andreou, M Jąkalski, K Duzowska, N Filipowicz, A Kostecka, H Davies, ... International Journal of Cancer, 2024 | 1 | 2024 |
| CSF liquid biopsies reveal disease status and resistance mechanisms in children undergoing targeted therapy for malignant brain tumors K Han, KS Smith, A Kostecka, S Dhanda, H Lin, M Mikkelsen, ... Clinical Cancer Research 30 (21_Supplement), B015-B015, 2024 | | 2024 |
| M-PACT: Methylation-based predictive algorithm for CNS tumor liquid biopsies TT Fischer, KS Smith, K Han, A Kostecka, H Lin, D Senfter, T Wedig, ... Clinical Cancer Research 30 (21_Supplement), B012-B012, 2024 | | 2024 |
| Robust disease monitoring using CSF liquid biopsies collected from children undergoing cellular therapy for malignant central nervous system tumors A Kostecka, KS Smith, K Han, H Lin, D Langfitt, T Walhart, S Gottschalk, ... Clinical Cancer Research 30 (21_Supplement), PR014-PR014, 2024 | | 2024 |
| LOCOREGIONAL ADMINISTRATION OF B7-H3-CAR T CELLS EXPRESSING 41BB LIGAND FOR PEDIATRIC PATIENTS WITH PRIMARY CNS TUMORS: PRELIMINARY RESULTS FROM A PHASE I STUDY KC Bertrand, A Kostecka, K Smith, K Han, J Chiang, S Pinto, D Tlais, ... Neuro-Oncology 26 (Supplement_8), viii88-viii88, 2024 | | 2024 |
| DISSECTING CDK4/6 INHIBITOR RESISTANCE MECHANISMS IN RECURRENT PEDIATRIC BRAIN TUMORS WITH LONGITUDINAL CSF LIQUID BIOPSIES FROM THE SJDAWN CLINICAL TRIAL K Han, A Kostecka, KS Smith, S Dhanda, H Lin, M Mikkelsen, ... Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
| RESULTS FROM SJDAWN: A ST JUDE CHILDREN’S RESEARCH HOSPITAL PHASE 1 STUDY EVALUATING MOLECULARLY DRIVEN DOUBLET THERAPIES FOR ALL CHILDREN WITH REFRACTORY OR RECURRENT CENTRAL … GW Robinson, BA Orr, SK Dhanda, T Lin, ND Sabin, K Han, A Kostecka, ... Neuro-Oncology 26 (Suppl 4), 0, 2024 | | 2024 |
| Development of a small-molecule epigenetic regenerative therapy. Subcutaneous administration of alginate formulations with high loads of zebularine and retinoic acid promotes … P Slonimska, J Baczynski-Keller, R Platek, M Deptula, M Dzierzynska, ... bioRxiv, 2024.09. 18.613177, 2024 | | 2024 |
| Beyond Tumors: Reduced survival linked to pathogenic PIK3CA and TP53 post-zygotic variants in uninvolved mammary tissue of breast cancer patients with recurrent disease M Andreou, K Chojnowska, N Filipowicz, M Horbacz, P Madanecki, ... medRxiv, 2024.10. 04.24313634, 2024 | | 2024 |
| Comparative genomics of geobacillus species sensitive to TP-84 bacteriophage: Identification of the bacterial defense systems A Żylicz-Stachula, K Myszczyński, M Koczkowska, A Kostecka, M Horbacz, ... Laboratory of Genetic Engineering, 2022 | | 2022 |
| Correction to: Reactivation of TAp73 tumor suppressor by protoporphyrin IX, a metabolite of aminolevulinic acid, induces apoptosis in TP53-deficient cancer cells A Sznarkowska, A Kostecka, A Kawiak, P Acedo, M Lion, A Inga, ... Cell Division 14, 1-3, 2019 | | 2019 |
